For UK pharmaceutical and life sciences leaders
Your evidence package may not be built for how NICE actually decides
The UK's appraisal process has distinct comparator requirements, clinical thresholds, and stakeholder expectations that differ from every other market. A strategy designed elsewhere rarely translates without significant rework.
Two minutes. Solva follows up with specific market access options.
- Repeated requests for additional evidence from NICE committees
- Longer than expected appraisal timelines, delaying patient access
- Negative or restricted recommendations from NICE
- Suboptimal pricing and reimbursement outcomes
- Missed market opportunities and reduced product uptake in the NHS.
- Increased workload for market access and HEOR teams due to repeated submissions and evidence generation
- Diversion of resources from other strategic initiatives to address NICE gaps
- Lost revenue from delayed or restricted market access in the NHS
- Increased costs associated with additional evidence generation and resubmissions
- Delayed patient access to innovative medicines and treatments
- Suboptimal patient outcomes due to lack of access to preferred therapies
- Damage to the company's reputation as an innovator and partner within the UK healthcare system
- Negative perception among healthcare professionals and patient advocacy groups
No verified UK data available
Source: No verified UK data available
Frequently asked questions
Why does this problem persist?
NICE market access in the UK requires a UK-specific strategy. The evidence requirements, comparators, and stakeholder landscape are different from every other market. Most global pharma companies underestimate this.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.